ArticleFrontiers in immunology2026

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression.

Alexandre Pérez-González et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.